Development of a novel therapy for Lipo-oligosaccharide-induced experimental neuritis: Use of peptide glycomimics

Seigo Usuki, Kyoji Taguchi, Yi Hua Gu, Stuart A. Thompson, Robert K. Yu

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Recent etiological studies have revealed that molecular mimicry between the lipo-oligosaccharide (LOS) component of Campylobacter jejuni and gangliosides of peripheral nervous system plays an important role in the pathogenesis of Guillain-Barré syndrome (GBS). Previously, we demonstrated GD3 ganglioside molecular mimicry in a model of GBS in Lewis rats by sensitization with GD3-like LOS (LOSGD3) from C. jejuni. Since the neuropathophysiological consequences were due largely to the anti-GD3-like antibodies, we subsequently focused our effort upon eliminating the pathogenic antibodies using several strategies to mimic GD3 in this model. Here, we have validated this strategy by the use of peptide glycomimics based on epitopic mimicry between carbohydrates and peptides. We treated rats by i.p. administration of phage-displayed GD3-like peptides. One GD3-like peptide (PGD3-4; RHAYRSMAEWGFLYS) induced in treated rats a remarkable restoration of motor nerve functions, as evidenced by improved histopathology, rotarod performance, and motor nerve conduction velocity. PGD3-4 effectively decreased the titer of anti-GD3/anti-LOSGD3 antibodies and ameliorated peripheral nerve dysfunction in the sera of treated rats. The data suggest that peptide glycomimics of ganglioside may be potential powerful reagents for therapeutic intervention in GBS by neutralizing specific pathogenic anti-ganglioside antibodies.

Original languageEnglish (US)
Pages (from-to)351-362
Number of pages12
JournalJournal of Neurochemistry
Volume113
Issue number2
DOIs
StatePublished - Apr 1 2010

Fingerprint

Neuritis
Oligosaccharides
Rats
Gangliosides
Peptides
Molecular Mimicry
Campylobacter jejuni
Antibodies
Anti-Idiotypic Antibodies
Therapeutics
Bacteriophages
Neural Conduction
Peripheral Nervous System
Neurology
Peripheral Nerves
Restoration
Carbohydrates
Serum

Keywords

  • Campylobacter jejuni
  • Ganglioside GD3
  • Guillain-Barré syndrome
  • Lipo-oligosaccharide
  • Molecular mimicry
  • Phage display peptide

ASJC Scopus subject areas

  • Biochemistry
  • Cellular and Molecular Neuroscience

Cite this

Development of a novel therapy for Lipo-oligosaccharide-induced experimental neuritis : Use of peptide glycomimics. / Usuki, Seigo; Taguchi, Kyoji; Gu, Yi Hua; Thompson, Stuart A.; Yu, Robert K.

In: Journal of Neurochemistry, Vol. 113, No. 2, 01.04.2010, p. 351-362.

Research output: Contribution to journalArticle

@article{ebca68014f8a45978fcb66c51dc2543d,
title = "Development of a novel therapy for Lipo-oligosaccharide-induced experimental neuritis: Use of peptide glycomimics",
abstract = "Recent etiological studies have revealed that molecular mimicry between the lipo-oligosaccharide (LOS) component of Campylobacter jejuni and gangliosides of peripheral nervous system plays an important role in the pathogenesis of Guillain-Barr{\'e} syndrome (GBS). Previously, we demonstrated GD3 ganglioside molecular mimicry in a model of GBS in Lewis rats by sensitization with GD3-like LOS (LOSGD3) from C. jejuni. Since the neuropathophysiological consequences were due largely to the anti-GD3-like antibodies, we subsequently focused our effort upon eliminating the pathogenic antibodies using several strategies to mimic GD3 in this model. Here, we have validated this strategy by the use of peptide glycomimics based on epitopic mimicry between carbohydrates and peptides. We treated rats by i.p. administration of phage-displayed GD3-like peptides. One GD3-like peptide (PGD3-4; RHAYRSMAEWGFLYS) induced in treated rats a remarkable restoration of motor nerve functions, as evidenced by improved histopathology, rotarod performance, and motor nerve conduction velocity. PGD3-4 effectively decreased the titer of anti-GD3/anti-LOSGD3 antibodies and ameliorated peripheral nerve dysfunction in the sera of treated rats. The data suggest that peptide glycomimics of ganglioside may be potential powerful reagents for therapeutic intervention in GBS by neutralizing specific pathogenic anti-ganglioside antibodies.",
keywords = "Campylobacter jejuni, Ganglioside GD3, Guillain-Barr{\'e} syndrome, Lipo-oligosaccharide, Molecular mimicry, Phage display peptide",
author = "Seigo Usuki and Kyoji Taguchi and Gu, {Yi Hua} and Thompson, {Stuart A.} and Yu, {Robert K.}",
year = "2010",
month = "4",
day = "1",
doi = "10.1111/j.1471-4159.2010.06627.x",
language = "English (US)",
volume = "113",
pages = "351--362",
journal = "Journal of Neurochemistry",
issn = "0022-3042",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Development of a novel therapy for Lipo-oligosaccharide-induced experimental neuritis

T2 - Use of peptide glycomimics

AU - Usuki, Seigo

AU - Taguchi, Kyoji

AU - Gu, Yi Hua

AU - Thompson, Stuart A.

AU - Yu, Robert K.

PY - 2010/4/1

Y1 - 2010/4/1

N2 - Recent etiological studies have revealed that molecular mimicry between the lipo-oligosaccharide (LOS) component of Campylobacter jejuni and gangliosides of peripheral nervous system plays an important role in the pathogenesis of Guillain-Barré syndrome (GBS). Previously, we demonstrated GD3 ganglioside molecular mimicry in a model of GBS in Lewis rats by sensitization with GD3-like LOS (LOSGD3) from C. jejuni. Since the neuropathophysiological consequences were due largely to the anti-GD3-like antibodies, we subsequently focused our effort upon eliminating the pathogenic antibodies using several strategies to mimic GD3 in this model. Here, we have validated this strategy by the use of peptide glycomimics based on epitopic mimicry between carbohydrates and peptides. We treated rats by i.p. administration of phage-displayed GD3-like peptides. One GD3-like peptide (PGD3-4; RHAYRSMAEWGFLYS) induced in treated rats a remarkable restoration of motor nerve functions, as evidenced by improved histopathology, rotarod performance, and motor nerve conduction velocity. PGD3-4 effectively decreased the titer of anti-GD3/anti-LOSGD3 antibodies and ameliorated peripheral nerve dysfunction in the sera of treated rats. The data suggest that peptide glycomimics of ganglioside may be potential powerful reagents for therapeutic intervention in GBS by neutralizing specific pathogenic anti-ganglioside antibodies.

AB - Recent etiological studies have revealed that molecular mimicry between the lipo-oligosaccharide (LOS) component of Campylobacter jejuni and gangliosides of peripheral nervous system plays an important role in the pathogenesis of Guillain-Barré syndrome (GBS). Previously, we demonstrated GD3 ganglioside molecular mimicry in a model of GBS in Lewis rats by sensitization with GD3-like LOS (LOSGD3) from C. jejuni. Since the neuropathophysiological consequences were due largely to the anti-GD3-like antibodies, we subsequently focused our effort upon eliminating the pathogenic antibodies using several strategies to mimic GD3 in this model. Here, we have validated this strategy by the use of peptide glycomimics based on epitopic mimicry between carbohydrates and peptides. We treated rats by i.p. administration of phage-displayed GD3-like peptides. One GD3-like peptide (PGD3-4; RHAYRSMAEWGFLYS) induced in treated rats a remarkable restoration of motor nerve functions, as evidenced by improved histopathology, rotarod performance, and motor nerve conduction velocity. PGD3-4 effectively decreased the titer of anti-GD3/anti-LOSGD3 antibodies and ameliorated peripheral nerve dysfunction in the sera of treated rats. The data suggest that peptide glycomimics of ganglioside may be potential powerful reagents for therapeutic intervention in GBS by neutralizing specific pathogenic anti-ganglioside antibodies.

KW - Campylobacter jejuni

KW - Ganglioside GD3

KW - Guillain-Barré syndrome

KW - Lipo-oligosaccharide

KW - Molecular mimicry

KW - Phage display peptide

UR - http://www.scopus.com/inward/record.url?scp=77949755756&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949755756&partnerID=8YFLogxK

U2 - 10.1111/j.1471-4159.2010.06627.x

DO - 10.1111/j.1471-4159.2010.06627.x

M3 - Article

C2 - 20132479

AN - SCOPUS:77949755756

VL - 113

SP - 351

EP - 362

JO - Journal of Neurochemistry

JF - Journal of Neurochemistry

SN - 0022-3042

IS - 2

ER -